S

Sanofi

Global pharma company; vaccines and R&D

Overview

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Work here?Claim your company

About Sanofi

Simplify's Rating
Why Sanofi is rated
B+
Rated A on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation

Industries

BiotechnologyHealthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • October 2026 sales rose 14.3%, and management raised 2026 sales guidance to 13%-15%.
  • Novavax and Sanofi advanced a Phase 3 flu-COVID trial, unlocking future milestones.
  • Sanofi launched Nuvaxovid across Canada for 2026-2027, expanding its non-mRNA vaccine footprint.

What critics are saying

  • Sanofi ended Nurix's SAR448272 program in November 2026, erasing $455 million milestones.
  • Blueprint Medicines lost 229 jobs in August 2026, signaling repeated post-deal integration pain.
  • Dupixent concentration leaves Sanofi exposed if exclusivity slips before 2030.

What makes Sanofi unique

  • Dupixent reached €5.7 billion in Q3 2026, anchoring Sanofi’s immunology franchise.
  • Sanofi paired vaccines, rare disease, and immunology with Regeneron, Novavax, and Blueprint.
  • Its global vaccine manufacturing and commercial network supports Nuvaxovid and high-dose flu scale.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$9.4B

Above

Industry Average

Funded Over

8 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Stock Price

Company News

StreetInsider
Nov 12th, 2026
Windward Bio raises $225M in Nasdaq IPO and Sanofi private placement

Windward Bio Group AG, a clinical-stage biotechnology company based in Basel, Switzerland, priced its initial public offering (IPO) of 10,294,117 common shares at $17 per share. Underwriters have a 30-day option to buy up to 1,544,117 more shares at the IPO price. Sanofi Foreign Participations B.V. will buy $50 million of shares and pre-funded warrants in a concurrent private placement, also at the IPO price. Combined gross proceeds are expected to reach $225 million, before discounts, commissions, and expenses. Shares were expected to begin trading on the Nasdaq Global Select Market on November 13, 2026, under the ticker WWB. The offering is expected to close on November 16, 2026, and the private placement depends on the IPO closing. Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank are joint book-running managers.

Yahoo Finance
Nov 10th, 2026
BNP Paribas upgrades Sanofi as Dupixent sales hit $6.4B, up 34.8%

BNP Paribas upgraded Sanofi to Outperform from Neutral on Monday, November 9. The analyst rating helped the drugmaker rank eighth on a list of stocks analysts just upgraded, with average upside potential of 8%. Bulls point to growth in Dupixent, a widening product base, and rising profit through 2030. Dupixent, its treatment for eczema, asthma, and other inflammatory conditions, sold €5.7 billion in the third quarter, up 34.8%. Advanced therapies reach only about 20% of eczema patients, which leaves room to grow. Sanofi raised its 2026 outlook, and its finance chief expects operating profit to rise every year through 2030. Planning for Dupixent's eventual patent loss is management's top priority, and Sanofi has expanded its alliance with Regeneron to develop next-generation antibodies. Bears cite falling vaccine sales, a slightly negative price effect expected in 2027, and the discontinuation of two experimental drugs. Divestments will also cut 2027 sales by about €1.3 billion.

Yahoo Finance
Nov 3rd, 2026
Nurix shares plunge 35% after Sanofi ends drug programme worth up to $455M in milestones

Shares of Nurix Therapeutics (NRIX) fell 35% after hours on Tuesday, after partner Sanofi ended development of SAR448272, an experimental oral drug it licensed from Nurix. Sanofi is terminating the early-stage first-in-human trial. The compound was being studied for type 2 inflammatory and autoimmune conditions such as atopic dermatitis and asthma. The decision ends roughly $455 million in potential milestone payments, plus royalties, tied to the program. Nurix has received about $139 million from Sanofi under their 2019 deal, including $10 million when the trial began this year. Nurix said its cash runway guidance is unchanged. It held $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, which it expects will fund operations into the second half of 2029.

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Recently Posted Jobs

Sign up to get curated job recommendations

Sanofi is Hiring for 806 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs